ArticlePloS one2016
Melanins Protect Sporothrix brasiliensis and Sporothrix schenckii from the Antifungal Effects of Terbinafine.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Genome variation of Sporothrix schenckii and Sporothrix brasiliensis.PLoS neglected tropical diseases · 2026Article
- Antibiofilm activity of terbinafine, itraconazole and their combination against Sporothrix brasiliensis yeast-like form's biofilms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Genetic Manipulation inJournal of fungi (Basel, Switzerland) · 2026Review
- Antimicrobial peptides from arthropod venoms exhibit activity againstThe journal of venomous animals and toxins including tropical diseases · 2026Article
- Current Insights intoJournal of fungi (Basel, Switzerland) · 2025Article
- In vitro effects of the new antifungal compound manogepix (APX001) against the three most clinically relevant species of Sporothrix.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Therapeutic alternatives for sporotrichosis induced by wild-type and non-wild-type Sporothrix schenckii through in vitro and in vivo assessment of enilconazole, isavuconazole, posaconazole, and terbinafine.Scientific reports · 2025Article
- Novel Insights into Sporotrichosis and Diabetes.Journal of fungi (Basel, Switzerland) · 2024Review
- Neutrophil Oxidative Burst Profile Is Related to a Satisfactory Response to Itraconazole and Clinical Cure in Feline Sporotrichosis.Journal of fungi (Basel, Switzerland) · 2024Article
- Antifungal Activity of Chitosan againstJournal of fungi (Basel, Switzerland) · 2023Article
- Dark Pigments in Entomopathogenic Fungal Microsclerotia: Preliminary Evidence of a 1,8-Dihydroxynaphthalene-melanin-like Compound inJournal of fungi (Basel, Switzerland) · 2023Article
- CRISPR-based tools for targeted genetic manipulation in pathogenicMicrobiology spectrum · 2023Article
- Fungal Glycosidases inJournal of fungi (Basel, Switzerland) · 2023Review
- Unveiling the Morphostructural Plasticity of Zoonotic Sporotrichosis Fungal Strains: Possible Implications forJournal of fungi (Basel, Switzerland) · 2023Article
- Sporothrix globosa melanin regulates autophagy via the TLR2 signaling pathway in THP-1 macrophages.PLoS neglected tropical diseases · 2023Article
- Current Progress inJournal of fungi (Basel, Switzerland) · 2023Review
- New insights and advances on pyomelanin production: from microbial synthesis to applications.Journal of industrial microbiology & biotechnology · 2022Review
- Keratinocyte Response to Infection withJournal of fungi (Basel, Switzerland) · 2022Article
- Virulence Factors ofJournal of fungi (Basel, Switzerland) · 2022Review
- Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella.Medical mycology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Terbinafine is a recommended therapeutic alternative for patients with sporotrichosis who cannot use itraconazole due to drug interactions or side effects. Melanins are involved in resistance to antifungal drugs and Sporothrix species produce three different types of melanin. Therefore, in this study we evaluated whether Sporothrix melanins impact the efficacy of antifungal drugs. Minimal inhibitory concentrations (MIC) and minimal fungicidal concentrations (MFC) of two Sporothrix brasiliensis and four Sporothrix schenckii strains grown in the presence of the melanin precursors L-DOPA and L-tyrosine were similar to the MIC determined by the CLSI standard protocol for S. schenckii susceptibility to amphotericin B, ketoconazole, itraconazole or terbinafine. When MICs were determined in the presence of inhibitors to three pathways of melanin synthesis, we observed, in four strains, an increase in terbinafine susceptibility in the presence of tricyclazole, a DHN-melanin inhibitor. In addition, one S. schenckii strain grown in the presence of L-DOPA had a higher MFC value when compared to the control. Growth curves in presence of 2×MIC concentrations of terbinafine showed that pyomelanin and, to a lesser extent, eumelanin were able to protect the fungi against the fungicidal effect of this antifungal drug. Our results suggest that melanin protects the major pathogenic species of the Sporothrix complex from the effects of terbinafine and that the development of new antifungal drugs targeting melanin synthesis may improve sporotrichosis therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.